Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Resonance Health Ltd ( (AU:RHT) ) has provided an announcement.
Resonance Health Ltd has announced its intention to release its full-year results for FY25 and guidance for FY26 on the ASX by 29 August 2025. The company will host a webinar for investors and analysts to discuss these results, encouraging stakeholder engagement through interactive participation. This announcement reflects Resonance Health’s commitment to transparency and stakeholder communication, potentially impacting its market positioning and investor relations.
More about Resonance Health Ltd
Resonance Health is an Australian healthcare technology and services company providing globally recognized quantitative assessments for managing diseases and drug development. The company offers Software-as-Medical Devices (SaMDs) with regulatory clearances in the USA, Europe, UK, and Australia, including products like FerriScan®, FerriSmart®, HepaFatScan®, HepaFatSmart®, LiverSmart®, and CardiacT2*. Resonance Health also manages clinical trials and holds ISO 13485 certification for medical device design and manufacture.
Average Trading Volume: 213,597
Technical Sentiment Signal: Sell
Current Market Cap: A$17.89M
See more data about RHT stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money